Safety and immunogenicity of a plant-produced recombinant monomer hemagglutinin-based influenza vaccine derived from influenza A (H1N1)pdm09 virus: A Phase 1 dose-escalation study in healthy adults

Vaccine

Volumn 32, Issue 19, 2014, Pages 2251-2259

  Cummings, James F ^a   Guerrero, Melanie L ^a   Moon, James E ^a   Waterman, Paige ^a   Nielsen, Robin K ^a   Jefferson, Stacie ^b   Gross, F Liaini ^b   Hancock, Kathy ^b   Katz, Jacqueline M ^b   Yusibov, Vidadi ^c   Chichester A , Jessica ^d   Jones, R Mark ^d   Manceva D , Slobodanka ^d   Green J , Brian ^d   Stow, Mark ^d   Miao, Fudu ^d   Moonsammy, George ^d   Streatfield, Stephen J ^d  

^a WALTER REED ARMY INSTITUTE OF RESEARCH   (United States)

^b NATIONAL CENTER FOR IMMUNIZATION AND RESPIRATORY DISEASES   (United States)

^c USA Center for Molecular Biotechnology   (United States)

^d NONE

Author keywords

H1N1; Hemagglutinin; Influenza A; Plant produced; Recombinant vaccine

Indexed keywords

ALUMINUM HYDROXIDE; HEMAGGLUTININ; INFLUENZA VACCINE; MONOMER; RECOMBINANT VACCINE;

ADULT; ARTICLE; CONTROLLED STUDY; DRUG DOSE ESCALATION; DRUG SAFETY; FATIGUE; FEVER; HEADACHE; HUMAN; IMMUNOGENICITY; INFLUENZA A; INFLUENZA A (H1N1); INFLUENZA VACCINATION; INFLUENZA VIRUS A H1N1; INJECTION SITE ERYTHEMA; INJECTION SITE INDURATION; INJECTION SITE PAIN; INJECTION SITE REACTION; MALAISE; MYALGIA; NAUSEA; NORMAL HUMAN; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; VIRUS STRAIN; VOMITING;

H1N1; HEMAGGLUTININ; INFLUENZA A; PLANT-PRODUCED; RECOMBINANT VACCINE;

ADULT; ANTIBODIES, VIRAL; FEMALE; HEMAGGLUTININ GLYCOPROTEINS, INFLUENZA VIRUS; HUMANS; INFLUENZA A VIRUS, H1N1 SUBTYPE; INFLUENZA VACCINES; INFLUENZA, HUMAN; MALE; MIDDLE AGED; RECOMBINANT PROTEINS; SINGLE-BLIND METHOD; TOBACCO; VACCINES, SUBUNIT; VACCINES, SYNTHETIC; YOUNG ADULT;

EID: 84897110525     PISSN: 0264410X     EISSN: 18732518     Source Type: Journal    
DOI: 10.1016/j.vaccine.2013.10.017     Document Type: Article

References (48)

1. World Health Organization Media Centre Influenza (Seasonal). Fact sheet No. 211 2009, http://www.who.int/mediacentre/factsheets/fs211/en/index.html [accessed 26.3.12].
2. Garten R.J., Davis C.T., Russell C.A., Shu B., Lindstrom S., Balish A. Antigenic and genetic characteristics of swine-origin 2009 A(H1N1) influenza viruses circulating in humans. Science 2009, 325:197-201.
3. Novel Swine-Origin Influenza A (H1N1) Virus Investigation Team Emergence of a novel swine-origin influenza A (H1N1) virus in humans. N Engl J Med 2009, 360(25):2605-2615.
4. Hancock K., Veguilla V., Lu X., Zhong W., Butler E.N., Sun H., et al. Cross-reactive antibody responses to the 2009 pandemic H1N1 influenza virus. N Engl J Med 2009, 361:1945-1952.
5. WHO D-G statement 2009, http://www.who.int/mediacentre/news/statements/2009/h1n1_pandemic_phase6_20090611/en/index.html [accessed 27.03.12].
6. Matthews J.T. Egg-based production of influenza vaccine: 30 years of commercial experience. The Bridge (Nat Acad Eng) 2006, 36(3):17-24.
7. Schultz-Cherry S., Jones J.C. Influenza vaccines: the good, the bad, and the eggs. Adv Virus Res 2010, 77:63-84.
8. Michiels B., Govaerts F., Remmen R., Vermeire E., Coenen S. A systematic review of the evidence on the effectiveness and risks of inactivated influenza vaccines in different target groups. Vaccine 2011, 29(49):9159-9170.
9. Osterholm M.T., Kelley N.S., Sommer A., Belongia E.A. Efficacy and effectiveness of influenza vaccines: a systematic review and meta-analysis. Lancet Infect Dis 2012, 12(1):36-44.
10. Greenberg M.E., Lai M.H., Hartel G.F., Wichems C.H., Gittleson C., Bennet J., et al. Response to a monovalent 2009 influenza A (H1N1) vaccine. N Engl J Med 2009, 361:2405-2413.
11. Liang X.F., Wang H.Q., Wang J.Z., Fang H.H., Wu J., Zhu F.C., et al. Safety and immunogenicity of 2009 pandemic influenza A H1N1 vaccines in China: a multicentre, double-blind, randomised, placebo-controlled trial. Lancet 2010, 375:56-66.
12. Plennevaux E., Sheldon E., Blatter M., Reeves-Hoché M.K., Denis M. Immune response after a single vaccination against 2009 influenza A H1N1 in USA: a preliminary report of two randomised controlled phase 2 trials. Lancet 2010, 375:41-48.
13. Talaat K.R., Greenberg M.E., Lai M.H., Hartel G.F., Wichems C.H., Rockman S., et al. A single dose of unadjuvanted novel 2009 H1N1 vaccine is immunogenic and well tolerated in young and elderly adults. J Infect Dis 2010, 202:1327-1337.
14. Clark T.W., Pareek M., Hoschler K., Dillon H., Nicholson K.G., Groth N., et al. Trial of 2009 influenza A (H1N1) monovalent MF59-adjuvanted vaccine. N Engl J Med 2009, 361:2424-2435.
15. Pushko P., Kort T., Nathan M., Pearce M.B., Smith G., Tumpey T.M., et al. Recombinant H1N1 virus-like particle vaccine elicits protective immunity in ferrets against the 2009 pandemic H1N1 influenza virus. Vaccine 2010, 28(30):4771-4776.
16. López-Macías C., Ferat-Osorio E., Tenorio-Calvo A., Isibasi A., Talavera J., Arteaga-Ruiz O., et al. Safety and immunogenicity of a virus-like particle pandemic influenza A (H1N1) 2009 vaccine in a blinded, randomized, placebo-controlled trial of adults in Mexico. Vaccine 2011, 29(44):7826-7834.
17. Protein Sciences Corp White Paper 2011, http://www.proteinsciences.com/News/index.html#/16/ [accessed 27.03.12].
18. Yusibov V., Streatfield S.J., Kushnir N. Clinical development of plant-produced recombinant pharmaceuticals: vaccines, antibodies and beyond. Hum Vaccin 2011, 7:313-321.
19. Yusibov V., Rabindran S. Recent progress in the development of plant derived vaccines. Expert Rev Vaccines 2008, 7(8):1173-1183.
20. Sharma A.K., Sharma M.K. Plants as bioreactors: recent developments and emerging opportunities. Biotechnol Adv 2009, 27(6):811-832.
21. D'Aoust M.A., Couture M.M., Charland N., Trépanier S., Landry N., Ors F., et al. The production of hemagglutinin-based virus-like particles in plants: a rapid, efficient and safe response to pandemic influenza. Plant Biotechnol J 2010, 8:607-619.
22. Rybicki E.P. Plant-made vaccines for humans and animals. Plant Biotechnol J 2010, 8(5):620-637.
23. Chichester J.A., Musiychuk K., de la Rosa P., Horsey A., Stevenson N., Ugulava N., et al. Immunogenicity of a subunit vaccine against Bacillus anthracis. Vaccine 2007, 25(16):3111-3114.
24. Mett V., Lyons J., Musiychuk K., Chichester J.A., Brasil T., Couch R., et al. A plant-produced plague vaccine candidate confers protection to monkeys. Vaccine 2007, 25:3014-3017.
25. Shoji Y., Chichester J.A., Bi H., Musiychuk K., de la Rosa P., Goldschmidt L., et al. Plant-expressed HA as a seasonal influenza vaccine candidate. Vaccine 2008, 26:2930-2934.
26. Shoji Y., Bi H., Musiychuk K., Rhee A., Horsey A., Roy G., et al. Plant-derived hemagglutinin protects ferrets against challenge infection with the A/Indonesia/05/05 strain of avian influenza. Vaccine 2009, 27:1087-1092.
27. Shoji Y., Farrance C.E., Bautista J., Bi H., Musiychuk K., Horsey A., et al. A plant-based system for rapid production of influenza vaccine antigens. Influenza Other Respi Viruses 2012, 6:204-210.
28. D'Aoust M.A., Lavoie P.O., Couture M.M., Trépanier S., Guay J.M., Dargis M., et al. Influenza virus-like particles produced by transient expression in Nicotiana benthamiana induce a protective immune response against a lethal viral challenge in mice. Plant Biotechnol J 2008, 6(9):930-940.
29. De Leede L.G., Humphries J.E., Bechet A.C., Van Hoogdalem E.J., Verrijk R., Spencer D.G. Novel controlled-release Lemna-derived IFN-alpha2b (Locteron): pharmacokinetics, pharmacodynamics, and tolerability in a phase I clinical trial. J Interferon Cytokine Res 2008, 28(2):113-122.
30. McCormick A.A., Reddy S., Reinl S.J., Cameron T.I., Czerwinkski D.K., Vojdani F., et al. Plant-produced idiotype vaccines for the treatment of non-Hodgkin's lymphoma: safety and immunogenicity in a phase I clinical study. Proc Natl Acad Sci U S A 2008, 105(29):10131-10136.
31. Landry N., Ward B.J., Trépanier S., Montomoli E., Dargis M., Lapini G., et al. Preclinical and clinical development of plant-made virus-like particle vaccine against avian H5N1 influenza. PLoS ONE 2010, 5(12):e15559.
32. Medicago Inc News release 2011, http://www.medicago.com/English/news/News-Releases/News-ReleaseDetails/2011/Medicago-to-present-additional-positive-clinical-data-at-the-2011ESWI-influenza-conference1126562/default.aspx [accessed 26.01.12].
33. Zimran A., Brill-Almon E., Chertkoff R., Petakov M., Blanco-Favela F., Muñoz E.T., et al. Pivotal trial with plant cell-expressed recombinant glucocerebrosidase, taliglucerase alfa, a novel enzyme replacement therapy for Gaucher disease. Blood 2011, 118(22):5767-5773.
34. Musiychuk K., Stephenson N., Bi H., Farrance C.E., Orozovic G., Brodelius M., et al. A launch vector for the production of vaccine antigens in plants. Influenza Other Respi Viruses 2007, 1:19-25.
35. Shoji Y., Chichester J.A., Jones M., Manceva S.D., Damon E., Mett V. Plant-based rapid production of recombinant subunit hemagglutinin vaccines targeting H1N1 and H5N1 influenza. Hum Vaccin 2011, 7(Suppl.):41-50.
36. World Health Organization WHO Global Influenza Surveillance Network Manual for the laboratory diagnosis and virological surveillance of influenza 2011, http://whqlibdoc.who.int/publications/2011/9789241548090_eng.pdf [accessed 28.06.12].
37. Guidance for industry toxicity grading scale for healthy adult and adolescent volunteers enrolled in preventive vaccine clinical trials 2007, http://www.fda.gov/downloads/BiologicsBloodVaccines/GuidanceComplianceRegulatoryInformation/Guidances/Vaccines/ucm091977.pdf [accessed 12.04.12].
38. Nicholson K.G., Thompson C.I., Klap J.M., Wood J.M., Batham S., Newman R.W., et al. Safety and immunogenicity of whole-virus, alum-adjuvanted whole-virus, virosomal, and whole-virus intradermal influenza A/H9N2 vaccine formulations. Vaccine 2010, 28:171-178.
39. Wu J., Li W., Wang H.Q., Chen J.T., Lv M., Zhou J.C., et al. A rapid immune response to 2009 influenza A(H1N1) vaccines in adults: a randomized, double-blind, controlled trial. J Infect Dis 2010, 202:675-680.
40. Zhu F.C., Wang H., Fang H.H., Yang J.G., Lin X.J., Liang X.F., et al. A novel influenza A (H1N1) vaccine in various age groups. N Engl J Med 2009, 361:2414-2423.
41. Bernstein D.I., Edwards K.M., Dekker C.L., Belshe R., Talbot H.K., Graham I.L., et al. Effects of adjuvants on the safety and immunogenicity of an avian influenza H5N1 vaccine in adults. J Infect Dis 2008, 197:667-675.
42. Brady R.C., Treanor J.J., Atmar R.L., Keitel W.A., Edelman R., Chen W.H., et al. Safety and immunogenicity of a subvirion inactivated influenza A/H5N1 vaccine with or without aluminum hydroxide among healthy elderly adults. Vaccine 2009, 27:5091-5095.
43. Bresson J.L., Perronne C., Launay O., Gerdil C., Saville M., Wood J., et al. Safety and immunogenicity of an inactivated split-virion influenza A/Vietnam/1194/2004 (H5N1) vaccine: phase I randomised trial. Lancet 2006, 367:1657-1664.
44. Ehrlich H.J., Müller M., Oh H.M., Tambyah P.A., Joukhadar C., Montomoli E., et al. A clinical trial of a whole-virus H5N1 vaccine derived from cell culture. N Engl J Med 2008, 358:2573-2584.
45. Keitel W.A., Campbell J.D., Treanor J.J., Walter E.B., Patel S.M., He F., et al. Safety and immunogenicity of an inactivated influenza A/H5N1 vaccine given with or without aluminum hydroxide to healthy adults: results of a phase I-II randomized clinical trial. J Infect Dis 2008, 198:1309-1316.
46. Keitel W.A., Dekker C.L., Mink C., Campbell J.D., Edwards K.M., Patel S.M., et al. Safety and immunogenicity of inactivated, Vero cell culture-derived whole virus influenza A/H5N1 vaccine given alone or with aluminum hydroxide adjuvant in healthy adults. Vaccine 2009, 27:6642-6648.
47. Nolan T.M., Richmond P.C., Skeljo M.V., Pearce G., Hartel G., Formica N.T., et al. Phase I and II randomised trials of the safety and immunogenicity of a prototype adjuvanted inactivated split-virus influenza A (H5N1) vaccine in healthy adults. Vaccine 2008, 26:4160-4167.
48. Brewer J.M., Conacher M., Satoskar A., Bluethmann H., Alexander J. In interleukin-4-deficient mice, alum not only generates T helper 1 responses equivalent to Freud's complete adjuvant, but continues to induce T helper 2 cytokine production. Eur J Immunol 1996, 26:2062-2066.